Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent Kinase
出版年份 2021 全文链接
标题
Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent Kinase
作者
关键词
-
出版物
Cancers
Volume 13, Issue 21, Pages 5506
出版商
MDPI AG
发表日期
2021-11-03
DOI
10.3390/cancers13215506
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The Rise of Molecular Glues
- (2021) Stuart L. Schreiber CELL
- Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update
- (2021) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy
- (2021) Liguo Wang et al. Nature Chemical Biology
- Discovery and resistance mechanism of a selective CDK12 degrader
- (2021) Baishan Jiang et al. Nature Chemical Biology
- Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax
- (2021) Hannah M. King et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4
- (2020) Marı́a Maneiro et al. ACS Chemical Biology
- Development of CDK2 and CDK5 Dual Degrader TMX‐2172
- (2020) Nathanael Schiander Gray et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs
- (2020) Niall A. Anderson et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Symbiotic prodrugs (SymProDs) dual targeting of NFkappaB and CDK
- (2020) Sandeep Rana et al. Chemical Biology & Drug Design
- Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs
- (2020) Ronen Gabizon et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity
- (2020) Yonghan He et al. Nature Communications
- A novel landscape of nuclear human CDK2 substrates revealed by in situ phosphorylation
- (2020) Yong Chi et al. Science Advances
- A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL
- (2020) Bingqi Tong et al. ACS Chemical Biology
- The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K
- (2020) Mikołaj Słabicki et al. NATURE
- Prospecting for molecular glues
- (2020) Willem den Besten et al. Nature Chemical Biology
- Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs
- (2020) Michael J. Bond et al. ACS Central Science
- CDK12: A Potent Target and Biomarker for Human Cancer Therapy
- (2020) Shujing Liang et al. Cells
- First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo
- (2020) Mingming Wei et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Clinically Precedented Protein Kinases: Rationale for Their Use in Neurodegenerative Disease
- (2020) Caroline L. Benn et al. Frontiers in Aging Neuroscience
- Small-molecule-induced polymerization triggers degradation of BCL6
- (2020) Mikołaj Słabicki et al. NATURE
- Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion
- (2020) Xiaqiu Qiu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)
- (2019) Jiantao Hu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer
- (2019) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- Developing potent PROTACs tools for selective degradation of HDAC6 protein
- (2019) Zixuan An et al. Protein & Cell
- Defining a new nomenclature for the structures of active and inactive kinases
- (2019) Vivek Modi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer
- (2019) Jinglu Wang et al. FASEB JOURNAL
- Selective Degradation of CDK6 by a Palbociclib Based PROTAC
- (2019) Sandeep Rana et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Kinetics of Drug Binding and Residence Time
- (2019) Mattia Bernetti et al. Annual Review of Physical Chemistry
- Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6
- (2019) Baishan Jiang et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation
- (2019) George M Burslem et al. CANCER RESEARCH
- BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
- (2019) William Farnaby et al. Nature Chemical Biology
- Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16
- (2019) Xiaoyu Zhang et al. Nature Chemical Biology
- Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders
- (2019) Shang Su et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting CDK9 for treatment of colorectal cancer
- (2019) Muhammed H. Rahaman et al. Molecular Oncology
- CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax
- (2019) Smit Kour et al. MOLECULAR PHARMACOLOGY
- A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
- (2019) Longchuan Bai et al. CANCER CELL
- p63 is a cereblon substrate involved in thalidomide teratogenicity
- (2019) Tomoko Asatsuma-Okumura et al. Nature Chemical Biology
- Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation
- (2019) Shuai Wang et al. Nature Chemical Biology
- Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15
- (2019) Tyler B. Faust et al. Nature Chemical Biology
- Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820
- (2019) Xinlin Du et al. STRUCTURE
- Targeting CDK2 in cancer: challenges and opportunities for therapy
- (2019) Solomon Tadesse et al. DRUG DISCOVERY TODAY
- Development of selective mono or dual PROTAC degrader probe of CDK isoforms
- (2019) Fei Zhou et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands
- (2019) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex
- (2019) Dirksen E. Bussiere et al. Nature Chemical Biology
- A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
- (2019) Sajid Khan et al. NATURE MEDICINE
- Chemical Genetic Screens Identify Kinase Inhibitor Combinations that Target Anti-Apoptotic Proteins for Cancer Therapy
- (2018) Jacob I. Contreras et al. ACS Chemical Biology
- Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2
- (2018) Meidan Ying et al. BLOOD
- Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein
- (2018) Mohammad Abid et al. CURRENT MEDICINAL CHEMISTRY
- Kinase-targeted cancer therapies: progress, challenges and future directions
- (2018) Khushwant S. Bhullar et al. Molecular Cancer
- Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands
- (2018) Lara N. Gechijian et al. Nature Chemical Biology
- Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8
- (2018) John M. Hatcher et al. ACS Medicinal Chemistry Letters
- Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer
- (2018) Silvia Paola Corona et al. Drug Design Development and Therapy
- Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity
- (2018) Jinlei Bian et al. BIOORGANIC CHEMISTRY
- Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome
- (2018) Katherine A Donovan et al. eLife
- Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
- (2018) Sainan An et al. EBioMedicine
- Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy
- (2018) Sandeep Rana et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53
- (2018) John Hines et al. CANCER RESEARCH
- Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update
- (2018) Solomon Tadesse et al. JOURNAL OF MEDICINAL CHEMISTRY
- Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion
- (2018) George M. Burslem et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation
- (2018) Philipp M. Cromm et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
- (2018) Quinlan L. Sievers et al. SCIENCE
- CDK9: A key player in cancer and other diseases
- (2017) Lia Carolina Franco et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1
- (2017) Andrew P. Crew et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical Probe
- (2017) Philip G. Humphreys et al. JOURNAL OF MEDICINAL CHEMISTRY
- Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands
- (2017) Norihito Shibata et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?
- (2017) Stephen Philip et al. JOURNAL OF MEDICINAL CHEMISTRY
- Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
- (2017) Calla M Olson et al. Nature Chemical Biology
- Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
- (2017) Ting Han et al. SCIENCE
- Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy
- (2017) Caroline M. Robb et al. Oncotarget
- Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges
- (2017) Shaomeng Wang et al. Cold Spring Harbor Perspectives in Medicine
- Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia
- (2017) M. Ryan Corces et al. Frontiers in Oncology
- Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand
- (2016) Yosuke Demizu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy
- (2016) Yogesh A. Sonawane et al. JOURNAL OF MEDICINAL CHEMISTRY
- A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
- (2016) Mary E. Matyskiela et al. NATURE
- Treating cancer with selective CDK4/6 inhibitors
- (2016) Ben O'Leary et al. Nature Reviews Clinical Oncology
- Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
- (2016) C Yang et al. ONCOGENE
- Targeting cancer with kinase inhibitors
- (2015) Stefan Gross et al. JOURNAL OF CLINICAL INVESTIGATION
- Characterization of Human Cyclin-Dependent Kinase 12 (CDK12) and CDK13 Complexes in C-Terminal Domain Phosphorylation, Gene Transcription, and RNA Processing
- (2015) Kaiwei Liang et al. MOLECULAR AND CELLULAR BIOLOGY
- Mediator kinase inhibition further activates super-enhancer-associated genes in AML
- (2015) Henry E. Pelish et al. NATURE
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- Structure-Guided Design and Optimization of Small Molecules Targeting the Protein–Protein Interaction between the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities
- (2014) Carles Galdeano et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models
- (2014) T. Yin et al. MOLECULAR CANCER THERAPEUTICS
- Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
- (2014) Eric S. Fischer et al. NATURE
- Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor
- (2013) T K Albert et al. BRITISH JOURNAL OF PHARMACOLOGY
- Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
- (2013) I. Bajrami et al. CANCER RESEARCH
- Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
- (2013) J. Rader et al. CLINICAL CANCER RESEARCH
- Synthetic lethality between CCNE1 amplification and loss of BRCA1
- (2013) D. Etemadmoghadam et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- Disrupting the Scaffold to Improve Focal Adhesion Kinase-Targeted Cancer Therapeutics
- (2013) W. G. Cance et al. Science Signaling
- Small-Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1α
- (2012) Dennis L. Buckley et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction
- (2012) Dennis L. Buckley et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Mechanism of Regulation of Receptor Histidine Kinases
- (2012) Hedda U. Ferris et al. STRUCTURE
- Design and synthesis of estrogen receptor degradation inducer based on a protein knockdown strategy
- (2011) Yosuke Demizu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+breast cancer patients
- (2011) Maurizio Scaltriti et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1
- (2011) G Polier et al. Cell Death & Disease
- Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia
- (2010) R. Chen et al. BLOOD
- A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
- (2010) Marta Puyol et al. CANCER CELL
- Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs
- (2010) Vladimir Krystof et al. CURRENT DRUG TARGETS
- Perturbation of the Bcl-2 Network and an Induced Noxa/Bcl-xL Interaction Trigger Mitochondrial Dysfunction after DNA Damage
- (2010) Hernando Lopez et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- Formal total synthesis of (±)-cortistatin A
- (2010) Eric M. Simmons et al. TETRAHEDRON
- Biological Insights from Structures of Two-Component Proteins
- (2009) Rong Gao et al. Annual Review of Microbiology
- Nuclear CDKs Drive Smad Transcriptional Activation and Turnover in BMP and TGF-β Pathways
- (2009) Claudio Alarcón et al. CELL
- CDK8 expression in 470 colorectal cancers in relation to β-catenin activation, other molecular alterations and patient survival
- (2009) Ron Firestein et al. INTERNATIONAL JOURNAL OF CANCER
- Covalent Modifiers: An Orthogonal Approach to Drug Design
- (2009) Michele H. Potashman et al. JOURNAL OF MEDICINAL CHEMISTRY
- Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
- (2009) H Quach et al. LEUKEMIA
- Total Synthesis of (+)-Cortistatin A
- (2008) K. C. Nicolaou et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Synthesis of (+)-Cortistatin A
- (2008) Ryan A. Shenvi et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- CDK8 is a colorectal cancer oncogene that regulates β-catenin activity
- (2008) Ron Firestein et al. NATURE
- CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
- (2008) K Bettayeb et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More